Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western diet
Ji Hye Han, Tae Jung Oh, Ghayoung Lee, et al.
Diabetologia (2016) Vol. 60, Iss. 2, pp. 364-376
Open Access | Times Cited: 241

Showing 26-50 of 241 citing articles:

Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition
Debapriya Basu, Lesley-Ann Huggins, Diego Scerbo, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2018) Vol. 38, Iss. 9, pp. 2207-2216
Open Access | Times Cited: 122
SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
Katherine R. Tuttle, Frank C. Brosius, Matthew A. Cavender, et al.
American Journal of Kidney Diseases (2020) Vol. 77, Iss. 1, pp. 94-109
Open Access | Times Cited: 111
Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
Zhenghong Liu, Xiaoxuan Ma, Iqra Ilyas, et al.
Theranostics (2021) Vol. 11, Iss. 9, pp. 4502-4515
Open Access | Times Cited: 99
Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice
Byambasuren Ganbaatar, Daiju Fukuda, Masakazu Shinohara, et al.
European Journal of Pharmacology (2020) Vol. 875, pp. 173040-173040
Closed Access | Times Cited: 96
Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle‐stimulated endothelial senescence and dysfunction: protective effect of gliflozins
Sin‐Hee Park, Eugenia Belcastro, Hira Hasan, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 95
Inflammatory Cytokines in Diabetic Kidney Disease: Pathophysiologic and Therapeutic Implications
Javier Donate‐Correa, Carla Ferri, Fátima Sánchez-Quintana, et al.
Frontiers in Medicine (2021) Vol. 7
Open Access | Times Cited: 89
Canagliflozin attenuates isoprenaline-induced cardiac oxidative stress by stimulating multiple antioxidant and anti-inflammatory signaling pathways
Raquibul Hasan, Shoumen Lasker, Ahasanul Hasan, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 88
Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice
Mei Xue, Ting Li, Yue Wang, et al.
Clinical Science (2019) Vol. 133, Iss. 15, pp. 1705-1720
Open Access | Times Cited: 86
Empagliflozin attenuates transient cerebral ischemia/reperfusion injury in hyperglycemic rats via repressing oxidative–inflammatory–apoptotic pathway
Entesar F. Amin, Rehab Ahmed Rifaai, Rania G. Abdel‐latif
Fundamental and Clinical Pharmacology (2020) Vol. 34, Iss. 5, pp. 548-558
Closed Access | Times Cited: 86
Diabetes and COVID-19: The past, the present, and the future
Raymond Pranata, Joshua Henrina, Wilson Matthew Raffaello, et al.
Metabolism (2021) Vol. 121, pp. 154814-154814
Open Access | Times Cited: 86
SGLT2 Inhibitors and Mechanisms of Hypertension
Αlexandros Briasoulis, Omar Al Dhaybi, George L. Bakris
Current Cardiology Reports (2018) Vol. 20, Iss. 1
Closed Access | Times Cited: 83
Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer’s Disease and Ischemia-Related Brain Injury
Michał Wiciński, Eryk Wódkiewicz, Karol Górski, et al.
Pharmaceuticals (2020) Vol. 13, Iss. 11, pp. 379-379
Open Access | Times Cited: 82
Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment
Nunzia D’Onofrio, Celestino Sardu, Maria Consiglia Trotta, et al.
Molecular Metabolism (2021) Vol. 54, pp. 101337-101337
Open Access | Times Cited: 81
SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
Katherine R. Tuttle, Frank C. Brosius, Matthew A. Cavender, et al.
Diabetes (2020) Vol. 70, Iss. 1, pp. 1-16
Open Access | Times Cited: 80
Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
Kai‐Fan Tsai, Yung‐Lung Chen, Terry Ting-Yu Chiou, et al.
Antioxidants (2021) Vol. 10, Iss. 8, pp. 1166-1166
Open Access | Times Cited: 79
SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Angiotensin II)–Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprotein E) Knockout Mice
Rebeca Ortega, Aida Collado, Francisca Selles, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2019) Vol. 39, Iss. 8, pp. 1614-1628
Open Access | Times Cited: 77
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
Giuseppe Palmiero, Arturo Cesaro, Erica Vetrano, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5863-5863
Open Access | Times Cited: 77
Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis
Wen-Hsuan Tsai, Shih‐Ming Chuang, Sung-Chen Liu, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 74
SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models
Ioanna Andreadou, Robert M. Bell, Hans Erik Bøtker, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2020) Vol. 1866, Iss. 7, pp. 165770-165770
Open Access | Times Cited: 73
The impact of SGLT2 inhibitors on inflammation: A systematic review and meta-analysis of studies in rodents
Panagiotis Theofilis, Μarios Sagris, Evangelos Oikonomou, et al.
International Immunopharmacology (2022) Vol. 111, pp. 109080-109080
Closed Access | Times Cited: 66
Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function
Teresa Salvatore, Alfredo Caturano, Raffaele Galiero, et al.
Biomedicines (2021) Vol. 9, Iss. 10, pp. 1356-1356
Open Access | Times Cited: 64
Management of oxidative stress and inflammation in cardiovascular diseases: mechanisms and challenges
Thoria Donia, Abeer A. Khamis
Environmental Science and Pollution Research (2021) Vol. 28, Iss. 26, pp. 34121-34153
Closed Access | Times Cited: 63
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
Jun Tang, Lifang Ye, Qiqi Yan, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 58
Cardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?
Asmaa Elrakaybi, Katharina Laubner, Qian Zhou, et al.
Molecular Metabolism (2022) Vol. 64, pp. 101549-101549
Open Access | Times Cited: 53
Empagliflozin attenuates neurodegeneration through antioxidant, anti-inflammatory, and modulation of α-synuclein and Parkin levels in rotenone-induced Parkinson’s disease in rats
Sanaa A. Ahmed, Mahmoud M. A. Elsayed, Mohamed A. Kandeil, et al.
Saudi Pharmaceutical Journal (2022) Vol. 30, Iss. 6, pp. 863-873
Open Access | Times Cited: 38

Scroll to top